Artículos por temáticas

γ-Secretase in Alzheimer's disease

Hur JY.

Exp Mol Med. 2022 Apr;54(4):433-446. doi: 10.1038/s12276-022-00754-8. Epub 2022 Apr 8.

The Neuroprotective Potentiality of Flavonoids on Alzheimer's Disease

Calderaro A, Patanè GT, Tellone E, Barreca D, Ficarra S, Misiti F, Laganà G.

Int J Mol Sci. 2022 Nov 27;23(23):14835. doi: 10.3390/ijms232314835.

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review

Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y.

J Alzheimers Dis. 2022;85(3):1195-1204. doi: 10.3233/JAD-215423.

The Potential Role of Gut Microbiota in Alzheimer's Disease: From Diagnosis to Treatment

Varesi A, Pierella E, Romeo M, Piccini GB, Alfano C, Bjørklund G, Oppong A, Ricevuti G, Esposito C, Chirumbolo S, Pascale A.

Nutrients. 2022 Feb 5;14(3):668. doi: 10.3390/nu14030668.

Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review

Cámara-Calmaestra R, Martínez-Amat A, Aibar-Almazán A, Hita-Contreras F, de Miguel Hernando N, Achalandabaso-Ochoa A.

J Prev Alzheimers Dis. 2022;9(4):601-616. doi: 10.14283/jpad.2022.57.

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR.

JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793.

Protection against Alzheimer's disease by luteolin: Role of brain glucose regulation, anti-inflammatory activity, and the gut microbiota-liver-brain axis

Daily JW, Kang S, Park S.

Biofactors. 2021 Mar;47(2):218-231. doi: 10.1002/biof.1703. Epub 2020 Dec 21.

Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impairments: Lessons from preclinical studies

Talebi M, İlgün S, Ebrahimi V, Talebi M, Farkhondeh T, Ebrahimi H, Samarghandian S.

Biomed Pharmacother. 2021 Jan;133:111088. doi: 10.1016/j.biopha.2020.111088. Epub 2020 Dec 15.

Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets

Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM.

Mol Neurobiol. 2021 Jan;58(1):281-303. doi: 10.1007/s12035-020-02116-9. Epub 2020 Sep 15.

Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron

Saeedi M, Rashidy-Pour A.

Biomed Pharmacother. 2021 Jan;133:110995. doi: 10.1016/j.biopha.2020.110995. Epub 2020 Nov 21.

Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

Özdinler PH.

FEBS J. 2021 Mar;288(5):1457-1461. doi: 10.1111/febs.15529. Epub 2020 Sep 5.

Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage

Farr AC, Xiong MP.

Mol Pharm. 2021 Feb 1;18(2):593-609. doi: 10.1021/acs.molpharmaceut.0c00474. Epub 2020 Oct 9.

Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?

Kumar A, Nemeroff CB, Cooper JJ, Widge A, Rodriguez C, Carpenter L, McDonald WM.

Am J Psychiatry. 2021 Nov;178(11):1014-1025. doi: 10.1176/appi.ajp.2021.19080873.

Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy

Nazam F, Shaikh S, Nazam N, Alshahrani AS, Hasan GM, Hassan MI.

Mol Cell Biochem. 2021 Jul;476(7):2739-2752. doi: 10.1007/s11010-021-04120-6. Epub 2021 Mar 9.

A carte blanche approval in Alzheimer's

Nat Biotechnol. 2021 Jul;39(7):781. doi: 10.1038/s41587-021-00995-4.